Fleury (BSP:FLRY3) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:FLRY3 Fleury SA BSP:FLRY3
90 GF Score
Price R$16.41
GF Value R$17.48
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Fleury Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

BSP:FLRY3
90GF Score
Fleury SA BSP:FLRY3
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fleury (BSP:FLRY3) Overvalued in 2026?

Based on GuruFocus' analysis, Fleury stock appears to be undervalued. The current stock price of R$16.41 is trading 6.1% below its estimated GF Value™ of R$17.48. GuruFocus considers Fleury to be Fairly Valued.

Key valuation signals for BSP:FLRY3:

  • Interest Received:
  • GF Value™: R$17.48 vs. price of R$16.41 (6.1% below fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fleury Business Description

Address Avenida Morumbi 8.860, 8th floor, Brooklin, Sao Paulo, SP, BRA, 04703-002
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
90GF Score

Get the complete analysis for BSP:FLRY3

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$16.41
Price
R$17.48
GF Value